Skip to content
MARKETS / NYSE / QGEN
NYSE · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP

Qiagen N.v. QGEN

18 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.1B
▲ 5.7% YoY
$424.9M
▲ 408.3% YoY
$453.3M
▼ 10.5% YoY
In brief

What this company does

QIAGEN provides sample and assay technologies that enable customers to extract, detect and interpret molecular information from biological samples. It serves over 500,000 customers globally in Life Sciences and molecular diagnostics for clinical healthcare. As of December 31, 2025, the company employed approximately 5,700 people in over 35 locations worldwide. Its primary production and manufacturing facilities for consumable products are located in Germany, the United States, Spain and China. It sells its products in more than 160 countries. It classifies its products into two main categories: consumables and related revenues, and instruments and related services. QIAGEN N.V. is the holding company for more than 60 consolidated subsidiaries, many of which primarily distribute its products and services on a regional basis. QIAGEN was founded in 1984 and began operations in 1986, with a method to standardize and accelerate the extraction and purification of nucleic acids from biological samples.

Written from the business description in QIAGEN N.V.'s annual report to the U.S. Securities and Exchange Commission, filed 20 March 2026. Every sentence was checked against that document before publication.

Growth
USD 2.1B
Revenue, FY2025 · full 18-year series below
Revenue $B Net income $B
FY2025 · Revenue 2.1 · Net income 0.4
0.8B1.6B2008201120142017202020232025
Compound annual growth
−0.8%
+2.2%
+5.0%
+4.5%
+0.1%
+3.4%
+12.6%
+7.5%
+1.8%
+4.9%
+13.4%
+42.8%
+41.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +2.2% a year over five years — but profit grew faster: net income at +3.4%, earnings per share at +4.9%.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
20 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 22.3% · Net 20.3%
10%20%2008201120142017202020232025
ROE
FY2025 · ROE 11.6%
5%10%15%2008201120142017202020232025

Each USD of equity produced 12 cents of profit this year.

Cash & shareholders
USD 334.3M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 453.3
200M400M2008201120142017202020232025
Net buybacks $M Dividends $M
FY2025 · Dividends 54.2 · Net buybacks 280.1
200MDividendsNet buybacks201020122014201620182020202220242025

USD 54.2M in dividends and USD 280.1M in buybacks — 79% of the year's profit went back to shareholders.

Total assetsUSD 6.3B
EquityUSD 3.8B
CashUSD 839.0M
Gross debtUSD 1.7B
Net debtUSD 815.4M
Current ratio3.90×

Net debt stands at 22% of equity.

The 18-year record
18 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017201620152014201320122011201020092008
Revenue $B2.12.02.02.12.31.91.51.51.41.31.31.31.31.31.21.11.00.9
Operating income $B0.50.10.40.50.60.4−0.00.30.20.10.20.20.10.20.10.20.20.1
EBITDA $B0.70.30.60.70.80.60.20.50.40.30.40.40.30.40.30.30.20.2
Income tax $B0.10.00.10.10.10.1−0.00.00.1−0.00.00.0−0.00.00.00.00.00.0
Net income $B0.40.10.30.40.50.4−0.00.20.00.10.10.10.10.10.10.10.10.1
Free cash flow $B0.50.50.30.60.40.30.20.20.20.30.20.20.20.10.20.20.20.1
EPS, diluted $1.940.371.481.842.211.53−0.180.820.170.340.550.480.290.540.400.600.640.44
Dividend / sh $0.25·················
Payout %1300···············
ROE %11.62.39.412.917.413.5−1.67.41.63.15.04.32.54.93.85.8··
Shares out B·············0.240.230.000.23·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

Provenance
Company facts, as filed
How we verify · 0 failures in 88 reconciliationsAUDITED

Reconciled in 18 of 19 fiscal years. 7 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNYSE
Incorporated inoutside the United States — SEC code P7
Fiscal year endsDecember 31
Data on record since2008

Share this section

Download image